JSP Pharmaceutical Manufacturing (Thailand) Public Valuation
Is JSP-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of JSP-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: JSP-R (THB2.1) is trading above our estimate of fair value (THB0.88)
Significantly Below Fair Value: JSP-R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JSP-R?
Other financial metrics that can be useful for relative valuation.
What is JSP-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿996.57m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.9x |
Enterprise Value/EBITDA | 16.2x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does JSP-R's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 16.8x | ||
BLC Bangkok Lab And Cosmetic | 19.1x | n/a | ฿3.1b |
MEGA Mega Lifesciences | 16.6x | 11.8% | ฿33.1b |
INFINIUM Infinium Pharmachem | 24x | n/a | ₹2.7b |
OCPH October PharmaE | 7.6x | n/a | ج.م1.2b |
JSP-R JSP Pharmaceutical Manufacturing (Thailand) Public | 45.4x | n/a | ฿996.6m |
Price-To-Earnings vs Peers: JSP-R is expensive based on its Price-To-Earnings Ratio (45.4x) compared to the peer average (16.8x).
Price to Earnings Ratio vs Industry
How does JSP-R's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: JSP-R is expensive based on its Price-To-Earnings Ratio (45.4x) compared to the Asian Pharmaceuticals industry average (24.6x).
Price to Earnings Ratio vs Fair Ratio
What is JSP-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 45.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate JSP-R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.